ÂÜÀòÂÒÂ×

Martin Andrews has been a member of the board of directors since October 2018, and has over 30 years' of broad commercial experience in pharmaceuticals. Mr. Andrews has spent many years in senior leadership roles at GlaxoSmithKline and in integrative leadership roles at the interface between R&D and commercial disciplines, has led numerous successful global product launches in pharmaceuticals and vaccines, and has deep medicine development and supply chain experience.

Most recently, Mr. Andrews was Senior Vice Presiden of Rare Diseases from November 2013 to July 2018 at GlaxoSmithKline and lead the development and launch of the world's first life saving gene therapy for children, Strimvelis, in addition to developing a pipeline of autologous ex-vivo gene therapy medicines which were recently acquired by Orchard Therapeutics. Prior to leaving GSK, Mr. Andrews was a Board Member of Orchard Therapeutics, the Alliance for Regenerative Medicine and is a Director of New Context Ltd, a consultancy specializing in rare disease, gene therapy and vaccine commercialization. Mr. Andrews received a B.Sc in Biology from the University of Salford, Manchester. We believe that Mr Andrews is qualified to serve on our board of directors because of his experience in the pharmaceutical industry.